Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758682 | 0.90 | MAOB (0.61) | MAOBMRGPRX4ARFFAR1NR3C1 | |
| SCHEMBL28961976 | 0.83 | MAOB (0.89) | MAOBARFFAR1NR3C1CYP19A1 | |
| SCHEMBL13047783 | 0.82 | FFAR1 (0.46) | MRGPRX4ARFFAR1MGAMGAA | |
| SCHEMBL22817113 | 0.81 | MAOB (0.49) | MAOBMRGPRX4CYP19A1 | |
| SCHEMBL8546657 | 0.80 | MERTK (0.52) | ARCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL21327244 | 0.80 | ALOX5 (0.58) | MAOBMRGPRX4MGAMGAASI | |
| SCHEMBL3758648 | 0.79 | HPGD (0.64) | MRGPRX4 | |
| SCHEMBL9357892 | 0.78 | RHEB (0.44) | FFAR1MGAMGAASIMGAM2 | |
| SCHEMBL403151 | 0.78 | MAOB (1.00) | MAOBARCYP19A1GAAEGLN2 | |
| SCHEMBL23484641 | 0.76 | XDH (0.46) | MAOBMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435462-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | Pfizer Limited (GB) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136940-A1 | NOVEL GLUCOCORTICOID RECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | GLOSSOP PAUL ALAN | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303758-A1 | Novel Glucocorticoid Receptor Agonists | NR3C1, NR3C2, MC2R | MAOB 3226/4885MRGPRX4 8/4885KDM4C 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.